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Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder. The debilitating choreic
movements that plague HD patients have been
attributed to striatal degeneration induced by the
loss of cortically supplied brain-derived neurotrophic
factor (BDNF). Here, we show that in mouse models
of early symptomatic HD, BDNF delivery to the stria-
tum and its activation of tyrosine-related kinase B
(TrkB) receptors were normal. However, in striatal
neurons responsible for movement suppression,
TrkB receptors failed to properly engage postsyn-
aptic signaling mechanisms controlling the induc-
tion of potentiation at corticostriatal synapses.
Plasticity was rescued by inhibiting p75 neurotrophin
receptor (p75NTR) signaling or its downstream
target phosphatase-and-tensin-homolog-deleted-
on-chromosome-10 (PTEN). Thus, corticostriatal
synaptic dysfunction early in HD is attributable to a
correctable defect in the response to BDNF, not its
delivery.
INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder resulting from a CAG expansion in the
huntingtin gene (The Huntington’s Disease Collaborative
Research Group, 1993). The earliest signs of pathology in HD
are in the striatum (Menalled and Chesselet, 2002; Raymond
et al., 2011), a subcortical structure involved in the control of
movement and action selection (Gerfen and Surmeier, 2011).
The striatum exerts this control by transforming excitatory
synaptic input from the cerebral cortex into patterned activity
in two parallel projection systems: so-called direct and indirect
pathways. Activity in direct pathway spiny projection neurons
(dSPNs) promotes action, whereas activity in indirect pathway
spiny projection neurons (iSPNs) suppresses action (Gerfen178 Neuron 83, 178–188, July 2, 2014 ª2014 Elsevier Inc.and Surmeier, 2011). A deficit in the ability of cortical circuits to
drive iSPNs has long been hypothesized to underlie unwanted
movement in the early stages of HD (Zuccato et al., 2010). In
recent years, this loss has been attributed to impaired expres-
sion and release of brain-derived neurotrophic factor (BDNF)
by corticostriatal terminals (Gauthier et al., 2004; Zuccato and
Cattaneo, 2007).
To gain a better mechanistic grasp of how alterations in BDNF
signaling might selectively affect how iSPNs translate cortical in-
puts, the corticostriatal network was studied in brain slices from
hemizygous BACHD mice crossed with reporter lines for dSPNs
and iSPNs (Andre´ et al., 2011; Gerfen and Surmeier, 2011; Gray
et al., 2008). The BACHD mouse is a transgenic model of HD in
which the full-length human mutant huntingtin (mHtt) gene has
been inserted using a bacterial artificial chromosome (BAC)
(Gray et al., 2008). These mice display progressive motor and
physiological deficits that are pronounced by 6 months of age
(Andre´ et al., 2011; Gray et al., 2008). To our surprise, striatal
levels of BDNF and messenger RNA (mRNA) for its receptor—
the TrkB receptor (TrkBR)—appeared normal in symptomatic
BACHD mice. This also was true in the Q175 knockin mouse
model of HD, which displays a similar progressive motor and
physiological phenotype (Menalled et al., 2012; Heikkinen
et al., 2012). Moreover, activity-dependent phosphorylation of
TrkBRs—the first step in postsynaptic BDNF signaling—was
normal in striata from 6-month-old BACHD mice. However,
downstream TrkBR signaling through Akt was significantly
impaired. This deficit was attributable to upregulation in the
expression of phosphatase-and-tensin-homolog-deleted-on-
chromosome-10 (PTEN) and amplification of BDNF signaling
through p75 neurotrophic receptor (p75NTR)—a well known
inhibitor of TrkBR signaling (Song et al., 2010).
RESULTS
BDNF Expression and Delivery to the Striatum Was
Normal in HD Mice
At the outset of our study, the expression of BDNF mRNA in the
cortex of BACHD and Q175 heterozygous knockin mice was
assessed using quantitative PCR (qPCR). In contrast to the
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Figure 1. BDNF mRNA and Protein Levels Are Unaltered in BACHD
Mutant Mice
(A) Diagram depicting cortical production and expression of BDNF, which is
delivered to the striatum (top). Map of six primer sets used spanning the
mouse BDNF gene (NCBI accession number NM_001048141.1; bottom).
1 = Bdnf_Yang_IV; 2 = Bdnf_Zuccato; 3 = Bdnf_Yang_CDS; 4 = Bdnf_H03;
5 = Bdnf_A03; 6 = Bdnf_Conforti. str, striatum; ctx, cortex.
(B) Boxplots showing relative cortical BDNF mRNA expression in 5- to
6-month-old BACHD mice (WT: n = 6; mutant: n = 5), as measured with qPCR
(right).
(C) Western blots showing relative (Rel.) BDNF protein levels (normalized
to tubulin) in the cortex and dorsal striatum of 6- to 8-month-old WT and
BACHD mice (WT: n = 3; HD: n = 3).
(D) Boxplots showing relative cortical BDNF mRNA expression in 5- to
6-month-old heterozygous Q175 knockin mice (WT: n = 5–6; Q175: n = 5–6).
*p < 0.05, Mann-Whitney nonparametric test.
Error bars are all SEM. Boxplot boxes indicate upper and lower quartiles;
whiskers indicate upper and lower 90%.
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Figure 2. Signaling Downstream of TrkBRs Is Attenuated in the
BACHD Striatum
(A) Relative expression of phosphorylated TrkBR (pTrkB) protein (normalized
to actin) in the dorsal striatum after incubation in 3 mM (left) or 17 mM (right)
KCl. KCl (17 mM) elevated phosphorylation of TrkBRs in WT dorsal striatum
(3 mM: n = 5; 17 mM: n = 5).
(B) Incubation in 17 mM KCl elevates pTrkBR protein expression (normalized
to actin) similarly in WT and BACHD dorsal striatum (WT: n = 4; HD: n = 4). Data
are normalized to WT median.
(C) Incubation in 17mMKCl led to significantly reduced phosphorylation of Akt
in the dorsal striatum of BACHD mice (WT: n = 5; HD: n = 5). Phosphorylated
Akt (pAkt) is expressed as the ratio of pAkt over total Akt. All data are from 6-
to 9-month-old mice. Representative western blot lanes are shown at the
bottom. *p < 0.05, Mann-Whitney nonparametric test.
Error bars are all SEM. Boxplot boxes indicate upper and lower quartiles;
whiskers indicate upper and lower 90%.
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Impaired TrkBR Signaling in Huntington’s Diseaseoriginal description of these mice (Gray et al., 2008), we found no
evidence of reduced abundance of cortical BDNF mRNA in
BACHD mice at either 2 or 6 months of age, nor did we find
any evidence of reduced BDNF protein levels in either the cortex
or striatum (Figures 1A–1C; Figure S1A available online). To
determine if this was peculiar to this HD model, we examined
6-month-old heterozygous Q175 knockin mice, but again, no
reduction in cortical BDNF mRNA expression was found (Fig-
ure 1D). Several previously published qPCR primer sets were
examined to ensure that our results were not simply a conse-
quence of primer choice or poor amplification efficiency. All of
them yielded similar results. One possible explanation for the
discrepancy is that previous work relied on a single, highly vari-
able ‘‘reference gene’’ for normalization of transcript abundance
rather than aweighted average of several more stable transcripts
(Pfister et al., 2011) (Figure 1; Figure S1D and Table S1).
Although its cortical and striatal levels were not reduced in the
HD models, BDNF release from cortical terminals and activation
of postsynaptic TrkBRs could be impaired (Gauthier et al., 2004).
To test this idea, two assays were performed. First, qPCR was
used to assess the expression of full-length or truncated TrkBR
mRNA in iSPNs and dSPNs isolated by fluorescence-activatedcell sorting (FACS). No change in TrkBR expression was found
in either type of SPN in symptomatic (5–6 months old) BACHD
mice (Figure S1C). Next, depolarization-induced phosphoryla-
tion of striatal TrkBRs was used as an assay of BDNF release
and receptor binding. Modest depolarization of wild-type (WT)
brain slices by incubation in elevated extracellular KCl (17 mM)
for 10 min significantly increased phophorylation of striatal
TrkBRs (Figure 2A). However, TrkBR phosphorylation induced
by depolarization was identical in 6- to 9-month-old WT and
BACHD mice (Figure 2B).
Taken together, our data suggest that, in relatively young but
symptomatic BACHD and heterozygous Q175 mice, cortical
production of BDNF, its delivery to the striatum, and its ability
to bind and activate striatal TrkBRs were normal. Therefore, if
there is indeed a BDNF signaling defect in HD, it must be
downstream of TrkBRs at this age.
TrkBR Signaling Can Be Assessed with Cellular
Resolution
To test the hypothesis that TrkBR signaling was impaired, one of
its targets—Akt—was examined following induction of BDNF
release by depolarizing ex vivo brain slices. Indeed, the ratio ofNeuron 83, 178–188, July 2, 2014 ª2014 Elsevier Inc. 179
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Impaired TrkBR Signaling in Huntington’s Diseasephosphorylated Akt to total striatal Akt was significantly lower in
brain slices from BACHD mice than in those from WT mice
following circuit-level depolarization (Figure 2C), suggesting
there was an HD-related deficit in TrkBR signaling. To help
pinpoint the cellular site of this signaling deficit, RNA sequencing
(RNA-seq) was performed on mRNA from 5- to 6-month-old
BACHD dSPNs and iSPNs that had been isolated by FACS
(Figure S2; Tables S2 and S3). These data were then used to
predict alterations in signaling networks in HD iSPNs and dSPNs.
The top signaling network identified by this analysis was the
huntingtin network in both iSPNs and dSPNs (data not shown).
The next most prominently altered network was that of BDNF.
It is interesting that the BDNF signaling network was diminished
in BACHD iSPNs but elevated in dSPNs (Figures S2A and S2B).
Not only does this analysis suggest that the BDNF/TrkBR
signaling deficit is specific to iSPNs at this age, but it also
confirms the inference that there is not a general deficit in
BDNF delivery to the striatum.
To unequivocally ascertain whether TrkBR signaling was
impaired in SPNs, another assay was needed. Previous work
had shown that corticostriatal long-term potentiation (LTP) in
SPNs required BDNF activation of postsynaptic TrkBRs (Jia
et al., 2010). This form of synaptic plasticity is postsynaptically
induced and expressed, making it an ideal assay of postsynaptic
TrkBR signaling.
Although necessary, TrkBRs are not sufficient to induce LTP at
corticostriatal synapses. Postsynaptic N-methyl-D-aspartate
(NMDA) receptors (NMDARs) and G protein coupled receptors
(GPCRs) linked to activation of protein kinase A (PKA) also are
necessary for LTP induction (Calabresi et al., 2007; Kreitzer
and Malenka, 2008; Shen et al., 2008). In iSPNs, the obligate
GPCRs are adenosine A2a receptors (A2aRs). Coactivating
these three signaling pathways—TrkBR, NMDAR, and A2aR—
should lead to postsynaptically induced LTP in SPNs, which
could be measured using two-photon uncaging of glutamate
on dendritic spines, creating a bioassay with cellular resolution.
To this end, SPNs were voltage clamped at 90 mV in the pres-
ence of pharmacological activators of TrkBRs (BDNF, 50 ng/ml),
A2aRs (CGS21680, 200 nM), and NMDARs (NMDA, 5 mM). To
prevent active propagation of activity and indirect effects on
the striatal network, the Na+ channel blocker tetrodotoxin
(1 mM) was bath applied. At 90 mV, NMDARs are blocked by
Mg2+. To transiently unblock them and trigger LTP induction,
SPNs were depolarized four times to +20 mV for 1 s, resting
10 s between depolarizations (Figure S3A). This cell-specific
induction paradigm produced a significant, long-lasting
enhancement in postsynaptic glutamate receptor currents at
about one-third of the spines examined using two-photon laser
uncaging of glutamate (Figures 3A–3F; Figures S3B and S3C).
Coactivation of all three postsynaptic signaling pathways
(TrkBR, NMDAR, and A2aR) was necessary to induce potentia-
tion of uncaging-evoked excitatory postsynaptic currents
(uEPSCs), as disrupting any one signaling pathway (blocking
BNDF signaling through TrkBRs with 150 nM K252a or scav-
enging BDNF with 4 mg/ml TrkB-Fc; blocking NMDARs with
50 mM AP5; blocking A2aRs with 200 nM SCH58261) resulted
in the attenuation or loss of potentiation (Figure 3F). In dSPNs,
this protocol also worked when the A2aR agonist was replaced180 Neuron 83, 178–188, July 2, 2014 ª2014 Elsevier Inc.with a D1 receptor agonist (Figure 3G). Both extracellular
signal-regulated kinase (ERK) and phosphoinositide-3 kinase
(PI3K), which are known to be activated by TrkBRs, were neces-
sary to induce potentiation, as it was blocked by antagonizing
either one (Figure 3F). Most important, this provided a bioassay
for TrkBR signaling with the level of resolution needed.
As cortical pyramidal neurons that project to the striatum
release BDNF, but thalamic neurons that project to the striatum
do not (Altar et al., 1997), it was our working hypothesis that
BDNF-dependent synaptic potentiation was limited to cortico-
striatal synapses. To test this hypothesis, a channelrhodopsin
2 (ChR2) expression construct was virally delivered to sensori-
motor cortex pyramidal neurons or to intralaminar thalamic neu-
rons that project to the striatum. Two weeks after infection, brain
slices were prepared, and the responses of individual SPN
spines to adjacent ChR2 stimulation with a fixed minimal diam-
eter (approximately 1 mm) 473 nm blue laser were assayed in
the presence of 1 mM tetrodotoxin (TTX) and 100 mM4-aminopyr-
idine (4-AP) (Petreanu et al., 2009). In the region of the striatum
most closely linked to sensorimotor cortex, about 70% of iSPN
spines on distal dendrites (>100 mm from the soma) were respon-
sive to ChR2 stimulation in the cortically transduced mice (48 of
68 spines). In this same region, about 30% (32 of 115) of iSPN
spines in distal dendrites were responsive to ChR2 stimulation
in thalamically transduced mice. At corticostriatal synapses,
the probability of inducing synaptic potentiation was similar to
that seen previously (Figure 3H). In contrast, at thalamostriatal
synapses, the median probability of potentiation was zero (Fig-
ure 3H). Plasticity also was examined in SPNs from transgenic
mice expressing ChR2 in cortical, but not in thalamic, neurons
(Arenkiel et al., 2007). In these mice, potentiation was induced
in roughly half the connected spines (Figure 3H), consistent
with it being a corticostriatal phenomenon.
BDNF-Dependent Postsynaptic Plasticity Was Lost
in BACHD and Q175 iSPNs
To appraise the integrity of TrkBR signaling in SPNs expressing
mHtt, synaptic potentiation was examined in brain slices from
BACHD mice crossed into the SPN reporter lines (Figure 4A).
In slices from the brains of mice that were 6–8 months of
age—a time before frank cell loss (Gray et al., 2008) or gross
dendritic atrophy (Figure S4), but a time when there are clear
motor symptoms—uEPSC potentiation in dSPNs was normal
(Figure 4B). However, in iSPNs, potentiation was effectively
lost (Figure 4C). In younger (2–3 months old) BACHD mice,
uEPSC potentiation in iSPNs was reduced but not lost (Fig-
ure S5A), suggesting that the impairment was progressive.
Furthermore, the impairment in synaptic plasticity was not
unique to this HD model, as iSPNs from 6-month-old heterozy-
gous Q175 knockin mice had the same deficit (Figure 4D).
To verify that the plasticity deficit in HD neurons also was
present when corticostriatal terminals were engaged, a conven-
tional high-frequency stimulation (HFS) LTP induction protocol
was tested (Calabresi et al., 2007; Jia et al., 2010). In this pro-
tocol, BDNF release was induced by electrical stimulation of cor-
ticostriatal axons. In WT iSPNs, this protocol induced a robust
LTP (Figure 4E); however, the same induction protocol failed to
induce LTP in iSPNs from 6-month-old BACHD mice (Figure 4E;
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Figure 3. Induction of Synaptic Potentiation
at iSPN Dendritic Spines
(A) MIP of an iSPN from a 1-month-old D2BAC
mouse.
(B) Somatic uEPSCs triggered at the two labeled
spines in (A) before (pre) and 15 min after (post) the
induction protocol.
(C) Long-lasting heterogeneous potentiation of
four neighboring iSPN spines.
(D) The induction protocol potentiated approxi-
mately one-third of iSPN dendritic spines only
when it included the four depolarizing steps
to +20mV (depolarizations: n = 52 spines, 7 cells, 5
animals; no depolarizations: n = 30 spines, 5 cells,
3 animals). amp, amplitude.
(E) Spines potentiated similarly in juvenile
(1 month, n = 13, 5 animals) and aged (6- to
8-month-old) iSPNs (n = 13, 2 animals) and dSPNs
(n = 7, 1 animal). amp, amplitude.
(F) Boxplots showing the percentage of spines per
iSPN that potentiated (with [depol] and without [No
depol] the four depolarizing steps to +20 mV, from
[D]). No potentiation was seen without the depo-
larizing steps. Potentiation was attenuated by AP5
(50 mM; NMDA and glycine omitted; n = 19 spines,
3 cells, 2 animals), the TrkB inhibitor K252a
(150 nM; n = 31 spines, 4 cells, 2 animals), the
BDNF scavenger TrkB-Fc (4 mg/ml; BDNF omitted;
n = 23 spines, 3 cells, 2 animals), the PI3K inhibitor
LY294002 (50 mM; n = 32 spines, 4 cells, 2
animals), theMEK/ERK inhibitor U0126 (30 mM, n =
34 spines, 5 cells, 3 animals), or the A2a receptor
antagonist SCH58261 (200 nM, CGS21680
omitted; n = 47 spines, 6 cells, 3 animals).
(G) Optically evoked EPSCs were potentiated in a
mixed population of SPNs from mice expressing
ChR2 under the control of the Thy1 promoter
(induction [Ind]: n = 42 spines, 4 animals, 7 cells; no
induction [No Ind]: n = 27 spines, 2 animals, 5 cells; both the A2a adenosine [200 mM CGS21680] and D1 dopamine [5 mM 6-Chloro-PB hydrobromide] receptor
agonists included in bath).
(H) Photomicrographs showing cortical (left) and thalamic (right) injection sites of AAV-ChR2 in 1- to 2-month-old D2BAC mice. Optogenetically evoked EPSCs
weremore readily potentiated in iSPN dendritic spines receiving cortical (n = 48 spines, 5 cells, 3 animals) versus thalamic (n = 32 spines, 9 cells, 3 animals) inputs.
Ind, induction; No Ind, no induction.
*p < 0.05, Fisher’s exact test (compared to depol). #p < 0.05 Fisher’s exact test (compared to No depol).
Error bars are all SEM. Boxplot boxes indicate upper and lower quartiles; whiskers indicate upper and lower 90%.
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Impaired TrkBR Signaling in Huntington’s Diseasebaseline EPSP amplitude was 3.01 ± 0.72 mV in WT iSPNs and
4.06 ± 1.11 mV in BACHD iSPNs, p = 0.4286, Mann-Whitney
nonparametric test). These results are consistent with those of
a previous study suggesting that LTP, as measured with field
potential recordings, is reduced in the striatum of rapidly
progressing R6/2 HD mice (Kung et al., 2007). Although these
experiments do not unequivocally demonstrate a synaptic locus
for the HD deficit, they are consistent with the impairment seen in
isolated, voltage-clamped spines.
A deficit in the ability to induce LTP should lead to both a
reduction in the number of glutamate receptors at corticostriatal
synapses and a decrease in dendritic spine density. To test
these predictions, corticostriatal miniature excitatory postsyn-
aptic currents (mEPSCs) were measured following electrical
stimulation of cortical afferent fibers in the presence of Sr2+
rather than Ca2+. Sr2+ substitution results in the asynchronous
release of quanta from stimulated terminals (Xu-Friedman and
Regehr, 2000). As predicted, the amplitude of mEPSCs wasreduced at corticostriatal synapses on iSPNs (but not dSPNs)
in brain slices from 6-month-old BACHD mice (Figure 4F).
Although there was no change in total dendritic length (Fig-
ure S4C), dendritic spine density was reduced in iSPNs (but
not dSPNs) from 6-month-old BACHD mice (Figure 4G). Thus,
the deficit in LTP induction was paralleled by structural adapta-
tions in HD iSPNs.
What was responsible for the LTP deficit in iSPNs expressing
mHtt? Previous work has demonstrated that ifenprodil-sensitive
extrasynaptic NMDARs increase in SPNs in the YAC128 mouse
model of HD (Milnerwood et al., 2010). The situation was similar
in BACHD iSPNs. As in the YAC128 iSPNs, the ratio of cortico-
striatal synaptic NMDAR to AMPAR currents was not altered in
BACHD iSPNs; however, in the presence of the glutamate trans-
port blocker DL-threo-b-benzyloxyaspartic acid (allowing the
engagement of extrasynaptic receptors), the NMDAR com-
ponent was greater in BACHD than WT iSPNs (Figures S5B
and S5C). 2PLUG experiments on distal spines of iSPNsNeuron 83, 178–188, July 2, 2014 ª2014 Elsevier Inc. 181
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F G
C D Figure 4. LTP Is Lost in SPNs in Two Mouse
Models of HD
(A) MIPs of iSPNs from 7-month-old WT and
BACHD mice.
(B–D) Boxplots showing the percentage of spines
per SPN that potentiate in response to the induc-
tion protocol in dSPNs in (B) (WT: n = 40 spines, 5
cells, 3 animals; HD: n = 38 spines, 5 cells, 3
animals) and iSPNs in (C) (WT: n = 40 spines,
5 cells, 2 animals; HD: n = 38 spines, 5 cells,
3 animals) from 6- to 8-month-old BACHD mice
and iSPNs from 6- to 8-month-old heterozygous
Q175 mice in (D) (WT: n = 28 spines, 5 cells,
4 animals; HD: n = 37 spines, 5 cells, 4 animals).
uEPSC potentiation is significantly attenuated in
both mutant lines. *p < 0.05, Fisher’s exact test.
(E) Electrical induction of LTP in 6- to 8-month-old
WT and BACHD iSPNs (WT: n = 6 cells, 3 animals;
HD: n = 5 cells, 3 animals). Percentage of EPSC
baseline after (25–30 min postinduction) is shown
to the right.
(F) Miniature EPSCs in response to strontium-
mediated asynchronous cortical glutamate
release in 6-month-old WT and BACHD iSPNs.
Stimulation artifact is truncated for presentation.
(G) Left: high-magnification MIPs of distal iSPN
dendrites from 6-month-oldWT and BACHDmice.
Top right: boxplots showing that amplitudes of
strontium-mediated cortical miniature EPSCs are
significantly reduced in BACHD iSPNs (WT: n = 8,
4 animals; HD: n = 11, 3 animals) but not dSPNs
(WT: n = 13, 3 animals; HD: n = 13, 2 animals).
Bottom right: boxplots showing that dendritic
spine density is decreased in 6- to 8-month-old
BACHD iSPNs but not dSPNs (WT iSPNs: n = 6, 2
animals; BACHD iSPNs: n = 7, 3 animals; dSPN
WT: n = 6, 2 animals; dSPN BACHD: n = 7,
2 animals). *p < 0.05, Mann-Whitney nonpara-
metric test.
Error bars are all SEM. Boxplot boxes indicate
upper and lower quartiles; whiskers indicate upper
and lower 90%.
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Impaired TrkBR Signaling in Huntington’s Diseasecorroborated this result (Figure S5D). Acute ifenprodil applica-
tion did not restore uEPSC potentiation in iSPNs from BACHD
mice, nor did it eliminate uEPSC potentiation in WT iSPNs
(Figures S5E and S5F). However, our data do not exclude
the possibility that sustained activation of extrasynaptic
NMDARs—over days or weeks—triggers adaptations that
underlie the synaptic deficit in HD models.
p75NTR Signaling Was Responsible for the Loss of
BDNF-Dependent Synaptic Potentiation
If BDNF and TrkBRs are not altered, why is BDNF-dependent
potentiation lost in BACHD iSPNs? Although downregulation
of the TrkBR linker proteins p52/p46 Shc has been reported in
an in vitro model of HD (Gine´s et al., 2010), these linkers are
not necessary for TrkBR-dependent synaptic potentiation (Mini-
chiello et al., 2002). In addition to activating TrkBRs, BDNF also
can robustly activate p75NTRs, albeit less potently (Bothwell,
1995; Zhang et al., 2008). The concentration of BDNF used to
mimic synaptic release in our experiments was near the IC50
of p75NTRs (Bothwell, 1995). Furthermore, although develop-182 Neuron 83, 178–188, July 2, 2014 ª2014 Elsevier Inc.mentally downregulated (Dechant and Barde, 2002), p75NTRs
continue to be expressed at low levels in adult SPNs from
both WT and BACHD mice (Figures S5G and S5H) and have
recently been implicated in HD pathology (Brito et al., 2013).
To test for their involvement, p75NTR expression was knocked
down by viral delivery of a small hairpin RNA (shRNA) (Fig-
ure S5I). Indeed, knockdown of p75NTR expression fully restored
BDNF-dependent synaptic potentiation in BACHD iSPNs
(Figure 5A).
To provide an additional test of p75NTR involvement, the
effects of inhibiting its signaling partners were examined.
p75NTR interacts directly with the Rho GDP dissociation inhibitor
(Rho-GDI), which controls activation of the small GTPase RhoA
(Yamashita and Tohyama, 2003). RhoA, in turn, activates
Rho-associated kinase (ROCK), which phosphorylates and acti-
vates PTEN (Yang and Kim, 2012). PTEN dephosphorylates
phosphoinositide products of PI3K, blunting its signaling (Song
et al., 2010). As shown earlier, PI3K signaling is necessary for
TrkBR-induced uEPSC potentiation. To test for the involvement
of Rho-GDI, we incubated slices with a TAT peptide targeting its
Figure 5. LTP Is Rescued in BACHD iSPNs
by Inhibition of p75NTR Signaling through
PTEN or Stimulation of FGF Receptors
(A) The percentage of potentiating spines per cell
(in response to the induction protocol) in 5- to
8-month-old BACHD iSPNs in control conditions
(no drug: n = 46 spines, 6 cells, and 2 animals; viral
injection of a control shRNA: n = 25 spines, 4 cells,
1 animal); after p75NTR knockdown by viral infec-
tion of p75NTR shRNA constructs (n = 32 spines, 5
cells, 2 animals); and in the presence of the p75NTR
inhibitor peptide pep5 (1 mM, n = 7 spines, 5 cells, 4
animals), the ROCK inhibitor Y-27632 (10 mM, n =
28 spines, 4 cells, 2 animals), the PTEN inhibitor
bpV(pic) (5 mM; n = 48 spines, 6 cells, 4 animals), or
PTEN knockdown by viral infection with a PTEN
shRNA construct (n = 29 spines, 4 cells, 2 animals).
(B) Relative change in PTEN mRNA expression in
iSPNs of 5- to 6-month-old BACHD mice (WT:
n = 6, HD: n = 6).
(C) Electrical induction of LTP in 5- to 6-month-old
BACHD iSPNs (n = 5 cells, 3 animals). Percentage
of EPSC baseline after (25–30 min postinduction)
is shown in the inset; BACHD iSPN data in the
absence of bpV(pic) from Figure 3E are shown for
comparison.
(D) The percentage of potentiating spines per cell
in 6- to 8-month-old BACHD iSPNs in the presence
of acidic FGF (aFGF) (20 ng/ml, n = 38 spines,
4 cells, 3 animals) or aFGF plus the FGFR
antagonist PLX052 (10 mM; n = 32 spines, 4 cells,
2 animals), with BDNF excluded.
(E) Relative change in FGFR1 expression in iSPNs
of 5- to 6-month-old BACHD mice (WT: n = 7; HD:
n = 6).
(F) Proposed model of LTP induction in an iSPN
spine.
*p < 0.05, Fisher’s exact test; **p <
0.05, Mann-Whitney nonparametric test; ns, not
significant.
Error bars are all SEM. Boxplot boxes indicate
upper and lower quartiles; whiskers indicate upper
and lower 90%.
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shita and Tohyama) (Ilag et al., 1999; Yamashita and Tohyama,
2003); Pep5 rescued BDNF potentiation in BACHD iSPNs (Fig-
ure 5A). Next, ROCK, the target of RhoA, was inhibited with
Y-27632 (10 mM); this also rescued potentiation (Figure 5A).
Last, PTEN was targeted; either pharmacologically inhibiting
PTEN with dipotassium bisperoxo(picolinato)oxovanadate (PTP
Inhibitor XV bpV(pic), 5 mM) or knocking down its expression
with a virally delivered shRNA rescued potentiation measured
by both 2PLUG (Figure 5A) and electrical stimulation (Figure 5C).
These results clearly point to p75NTR signaling through PTEN
as responsible for disrupting TrkBR signaling in HD iSPNs. This
signaling pathway is also present in WT iSPNs; however, phar-
macological inhibition of PTEN had no effect on synaptic poten-
tiation in WT iSPNs or dSPNs (Figure S5J). What was different in
HD iSPNs? The expression of p75NTR mRNA was not measur-
ably different in iSPNs isolated by FACS from HD striata (Figures
S5G and S5H). However, the expression of PTEN was signifi-
cantly elevated in BACHD iSPNs, but not dSPNs (Figure 5B),providing a mechanistic foundation for the enhancement of
p75NTR signaling.
If the HD deficit in TrkBR signaling is simply a consequence of
BDNFcoactivation of p75NTR, then the signaling of growth factors
that do not bind to p75NTR should be unaffected. In SPNs, fibro-
blast growth factor (FGF) binds to receptors that, like TrkBRs,
are tyrosine kinase receptors that promote LTP induction (Eswar-
akumar et al., 2005; Flajolet et al., 2008). Replacing BDNF with
FGF (20 ng/ml) led to normal synaptic potentiation in 6- to
8-month-old BACHD iSPNs (Figure 5D). Quantitative profiling of
iSPN mRNA from 6-month-old BACHD mice revealed that FGF
receptor 1 (FGFR1) mRNA expression was elevated compared
to controls (Figure 5E; Figure S5K), suggesting that FGFRs were
part of an attempt to compensate for the TrkBR signaling deficit.
DISCUSSION
For the past decade, the striatal pathology in HD has been attrib-
uted to a decrease in cortical BDNF delivery (Gauthier et al.,Neuron 83, 178–188, July 2, 2014 ª2014 Elsevier Inc. 183
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Cattaneo, 2007). As a consequence, BDNF replacement has
been viewed as a promising approach for slowing disease
progression (Canals et al., 2004; Zuccato and Cattaneo, 2007).
Although it does not exclude the possibility that, later in the
progression of the disease, such trafficking deficits manifest
themselves, our work argues that deficits in TrkBR and p75NTR
signaling precede them.
A cornerstone of the BDNF delivery hypothesis has been the
apparent drop in cortical BDNF mRNA expression in young
HD mouse models. In our hands, there was no evidence of
decreased cortical BDNF expression in either BACHD or hetero-
zygous Q175 mice at 6 months of age—a time point at which
behavioral and physiological deficits are evident (Andre´ et al.,
2011; Gray et al., 2008). The discrepancy between our results
and previous ones did not stem from primer design, as a variety
of published and unpublished primer sets yielded the same
result. However, the discrepancy could be due to differences in
the way transcript abundance was estimated. For qPCR, an
internal standard is necessary to correct the threshold cycle
number for variation in the amount of starting material.
Commonly, a ‘‘reference gene’’ is used for this purpose that is
assumed to be unaffected by the experimental intervention
being examined. Beta-actin or glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) transcripts often are used for this
purpose, as in the previous studies of BDNF abundance (see
Table S1). However, these two transcripts are not ideal stan-
dards, because of variability in their expression (Figure S1). A
more appropriate strategy is to use aweighted average of several
stable transcripts to derive a standard. Doing this led to the
conclusion that there was no change in BDNF mRNA levels in
cerebral cortex of BACHD and heterozygous Q175 HD models.
In agreement with this conclusion, the phosphorylation of striatal
TrkBRs in response to depolarization-induced release of BDNF
by cortical terminals was normal in tissue from BACHD mice.
It is worth noting, however, that in 6-month-old homozygous
Q175 knockin mice, there was a significant decrease in cortical
BDNF expression (Figure S1B), in agreement with the assertion
that mHtt can regulate BDNF expression when expressed at high
enough levels (Canals et al., 2004). However, because of the
more rapid disease progression in these mice (Menalled et al.,
2012; Heikkinen et al., 2012) comparisons to the BACHD model
are problematic. Moreover, the relevance of this gene-dose effect
to the human condition is uncertain (Wexler et al., 1987).
In spite of there being no detectable change in cortical BDNF
expression or striatal delivery in early-stage HD models, there
was a clear deficit in the postsynaptic response of iSPNs to
BDNF. To unequivocally assay postsynaptic TrkBR signaling
in a single, phenotypically defined neuron, a strategy for
inducing synaptic potentiation at visualized spines that did not
depend on activation of presynaptic fibers was developed. Un-
like synaptic potentiation at other synapses (Harvey and Svo-
boda, 2007; Tanaka et al., 2008), corticostriatal long-term syn-
aptic potentiation requires coactivation of three synaptic or
perisynaptic proteins: TrkBRs, NMDARs, and a Golf coupled re-
ceptor (A2aRs or D1Rs, depending on SPN type) (Calabresi
et al., 2007; Jia et al., 2010; Shen et al., 2008). There is no
requirement for presynaptic activity other than to release the184 Neuron 83, 178–188, July 2, 2014 ª2014 Elsevier Inc.agonists for these receptors. The only postsynaptic induction
requirement (beyond intracellular signaling) is membrane depo-
larization to relieve the Mg2+ block of NMDARs. In the presence
of agonists for these three receptors, four brief postsynaptic de-
polarizations (to open NMDARs) were all that was required to
produce lasting potentiation of axospinous, corticostriatal syn-
apses, as judged by focal uncaging of glutamate on spine heads
or optogenetic stimulation of corticostriatal terminals. Our study
(see Figure 3) demonstrates not only the factors necessary for
induction of corticostriatal potentiation but what is sufficient
for induction.
The ability to induce corticostriatal synaptic potentiation using
this protocol or with a conventional HFS protocol was lost
specifically in iSPNs from BACHD and heterozygous Q175
mice. Potentiation was normal in dSPNs. In BACHD iSPNs, there
were two structural correlates of the deficit. One was a reduction
in the average number of postsynaptic AMPARs, as estimated
by the amplitude of corticostriatal mEPSCs at membrane
potentials that were not permissive for NMDAR currents. The
other was a reduction in spine density. Both observations are
consistent with previous work suggesting that potentiated
axospinous synapses not only have more synaptic AMPARs
but are also more stable (Kasai et al., 2010; Kopec et al., 2006;
Mendez et al., 2010).
This cell-specific deficit in potentiation was attributable to
upregulation of p75NTR signaling through PTEN, resulting in
impaired TrkBR activation of PI3K and Akt. Striatal p75NTR
signaling is elevated in other HD models (Brito et al., 2013),
buttressing this conclusion. Both pharmacological and mole-
cular approaches supported this conclusion. Either decreasing
p75NTR expression or blocking its coupling to RhoA normalized
TrkBR signaling. Antagonizing the target of RhoA, ROCK, also
corrected TrkBR signaling. Either decreasing PTEN expression
with a shRNA or pharmacologically diminishing its activity
restored TrkBR signaling. The alteration in p75NTR signaling in
HD iSPNs was attributable to the upregulation of PTEN, not
p75NTR itself. Why PTEN was upregulated is unclear. It is
possible that PTEN trafficking is altered by mHtt, leading to
alterations in expression and function (Gericke et al., 2006).
One additional piece of evidence in support of the involvement
of p75NTR signaling was the finding that synaptic potentiation
was restored in HD iSPNs by FGF. FGFRs expressed by iSPNs
have previously been shown to promote the induction of cortico-
striatal synaptic potentiation through mechanisms similar to
those of TrkBRs (Flajolet et al., 2008). However, unlike BDNF,
FGF does not bind to p75NTR. Thus, astrocyte release of FGF
(Tooyama et al., 1993) and FGFR signaling might partially
compensate for the loss of trophic support derived from BDNF.
Our results also are concordant with work implicating Ras
Homolog Enriched in Striatum (Rhes) in HD pathogenesis (Sub-
ramaniam et al., 2009). Rhes inhibits Akt signaling (Harrison
et al., 2013), and the elimination of Rhes increases Akt phosphor-
ylation and diminishes the impact of mHtt (Harrison et al., 2013;
Harrison and Lahoste, 2013). Moreover, extrasynaptic NMDAR
signaling, which is upregulated in SPNs of HD models (Milner-
wood et al., 2010), increases Rhes expression (Okamoto et al.,
2009). Thus, extrasynaptic NMDAR signaling through Rhes and
p75NTR signaling through PTEN might synergize to suppress
Neuron
Impaired TrkBR Signaling in Huntington’s DiseaseAkt signaling, which is known to be necessary for neuronal
vitality (Humbert et al., 2002).
Diminished innervation of iSPNs, the anchors of the basal
ganglia circuitry responsible for motor suppression, can provide
a straightforward explanation for early hyperkinetic HD motor
symptoms (Gerfen and Surmeier, 2011;Menalled andChesselet,
2002; Raymond et al., 2011). Although this behavior may not be
fully manifest in rodent models at this age, complete removal of
TrkBR signaling in iSPNs leads to hyperlocomotion in otherwise
normal mice (Besusso et al., 2013). This deficit could, in turn,
trigger adaptations throughout the neural network linking the
striatum and cortex (Kozorovitskiy et al., 2012), resulting in
cortical pathology associated with HD (Cepeda et al., 2007). It
also is possible that enhanced p75NTR signaling in the cerebral
cortex induces pathology, as deficits in TrkBR signaling—
whether in the striatum or cortex—have profound effects on
neuronal function, as well as mHtt toxicity (Humbert et al.,
2002; Warby et al., 2005). While, in our slice preparation,
p75NTR activation is likely achieved by BDNF, it should be noted
that other ligands (such as proNGF or proBDNF) may contribute
to p75NTR engagement in vivo (Dechant and Barde, 2002; Fayard
et al., 2005; Song et al., 2010). Although it is unlikely that all of the
pathology inHDcan traced to a single cause, our studies strongly
suggest that, in the early stages of the disease, p75NTR antago-
nism should be part of an effective therapeutic strategy for
restoring normal BDNF and Akt signaling. Moreover, given that
its tissue distribution narrows and expression level falls with
development (Dechant and Barde, 2002), p75NTR antagonism
should be less likely to have unacceptable side effects in adult
HD patients than strategies targeting TrkBRs, which continue
to be robustly and widely expressed in the adult brain.
EXPERIMENTAL PROCEDURES
Electrophysiology
Parasagittal brain slices (275 mm) were prepared from D2BAC-EGFP (FVB),
Thy1-ChR2 (C57BL/6), BACHD (FVB) x D2BAC-EGFP (FVB), BACHD (FVB) x
D1BAC-EGFP (FVB), or Q175 (C57BL/6) transgenic mice following procedures
approved by the Northwestern University Animal Care and Use Committee, as
described elsewhere (Day et al., 2008). Patch pipettes were loaded with inter-
nal recording solution containing (in millimolar): 120 CsMeSO3, 5 NaCl,
10 tetraethylammonium-Cl (TEA-Cl), 10 HEPES, 5 Qx-314, 4 Mg-ATP, 0.3
Na-GTP, 0.2 Fluo-4 pentapotassium salt, and 0.05 Alexa Fluor 568 hydrazide
sodium salt (Invitrogen), pH 7.25; osmolality, 270–280 mOsm1. Slices were
transferred to a submersion-style recording chamber on a fixed-stage
Olympus BX51 upright microscope and perfused with 95%O2/5%CO2-
bubbled artificial cerebrospinal fluid (ACSF) containing (in millimolar): 124
NaCl, 3 KCl, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 1 NaH2PO4, and 16.66 glucose.
Electrophysiological recordings weremade using aMulticlamp 700B amplifier;
protocols were delivered and recorded using the custom-written freeware
packageWinFluor (John Dempster, Strathclyde University), as described else-
where (Day et al., 2008; Plotkin et al., 2011). Recordings were performed at
room temperature and filtered at 1 kHz. Strontium-mediated asynchronous
miniature EPSC amplitudes (2 mM Sr2+ in external recording solution) were
measured as previously described using an internal recording solution
composed of (in millimolar): 120 CsMeSO3, 15 CsCl, 8 NaCl, 10 TEA-Cl, 10
HEPES, 2–5 Qx-314, 0.2 EGTA, 2 Mg-ATP, and 0.3 Na-GTP (Ding et al., 2008).
Single Spine Synaptic Potentiation
SPNs were held at 90 mV in the presence of an ‘‘LTP cocktail’’ containing
50 ng/ml BDNF, 5 mM NMDA, 5 mM glycine, 1 mM TTX, 200 nM CGS21680,
1 mM sulpiride, 2 mM muscarine, 50 mM CPCCOEt, 1 mM MPEP, and 0.1%BSA, dissolved in HEPES-buffered ACSF, unless otherwise stated. In experi-
ments performed in dSPNs, CGS21680 was replaced with 5 mM 6-Chloro-PB
hydrobromide and 0.1% sodium metabisulfite. Muscarine had no detectable
effect on LTP induction and was thus omitted in most cases (in all compared
groups). This LTP cocktail was superfused (0.4 ml/hr) over the slice using
a syringe pump and multibarreled perfusion manifold (Cell MicroControls).
Baseline uEPSCs were recorded from approximately eight coplanar distal
(greater than 90 mm from soma) spines, separated by 200 ms, and averaged
three to eight times (5 s intertrial interval). The cell was then stepped
from 90 to 20 mV for 1 s, four times total, 10 s between steps. uEPSCs
were thenmeasured from the same spines in the samemanner 10–30min after
the depolarizing voltage steps. Unless otherwise indicated, represented time
points are 10–15 min postinduction. Potentiation was defined as an increase
in EPSC amplitude of at least 150% of baseline (based on Figure 1D;
Figure S5). Series resistance was monitored, and recordings with a change
of more than 20% were rejected from analysis.
Two-Photon Laser Scanning Microscopy, Two-Photon Laser
Uncaging, and ChR2 Stimulation
dSPNs and iSPNs were identified by somatic EGFP expression using
two-photon excited fluorescence, which was induced and detected using a
Prairie Ultima laser scanning microscope system (Prairie Technologies). Fluo-
rescent and bright-field images were viewed in register using a Dodt contrast
detector system. Cells were patched using video microscopy with a Hitachi
CCD camera and an Olympus 603/1.0 NA lens. Green (EGFP) and red (Alexa
Fluor 568) signals were acquired using 810 nm excitation (Verdi/Mira laser).
Following patch rupture, the internal solution was allowed to equilibrate for
10–15 min before imaging. High-magnification z series were acquired with
0.072 mm2 pixels, with 4 ms dwell time and 0.3 mm z-steps. At the end of
each experiment, whole-cell z series were acquired with 0.36 mm2 pixels,
with 10 ms dwell times and 1 mm z-steps. Glutamate uncaging was achieved
using a Chameleon-XR laser system (Coherent Laser Group). MNI-glutamate
(5 mM; Tocris, Cookson) was superfused over the slice through the same
syringe used to deliver the LTP cocktail. Glutamate was uncaged adjacent
to individual spines using 1 ms pulses of 720 nm light typically 10–20 mW in
power at the sample plane. Photolysis power was tuned via a third Pockels
cell modulator (Con Optics) to achieve uEPSCs averaging 5–15 pA. ChR2
stimulation was achieved with a Prairie Instruments blue laser (473 nm) and
shuttered to aminimal fixed diameter (approximately 1 mm). Presynaptic termi-
nals adjacent to individual distal spines were targeted. All ChR2 studies were
performed in the presence of 1 mM TTX, 100 mM 4-AP, and the LTP cocktail.
Electrical LTP Induction
iSPNs from parasagittal 6- to 7-month-old WT and BACHD mice were
patched with electrodes containing (in millimolar): 135 KMeSO4, 5 KCl,
0.5 CaCl2, 10 HEPES, 2 ATP-Mg, 0.5 GTP-Na, 5 phosphocreatine-Tris,
5 phosphocreatine-Na, and 0.3 EGTA. Recordings were made in continuously
perfused oxygenated Mg2+-free ACSF containing (in millimolar): 135 NaCl, 2.5
KCl, 25 NaHCO3, 1.25 NaH2PO4, 10 glucose, and 2 CaCl2. Electrical stimula-
tion was performed with a parallel bipolar electrode placed in the overlying
cortex. The HFS LTP induction protocol was composed of 1 s, 100 Hz trains
repeated four times at a 10 s interval and performed as described by others
(Jia et al., 2010). Series resistance was monitored, and recordings with a
change of more than 20% were rejected from analysis.
Stereotaxic ChR2 Injections
Stereotaxic injections of adeno-associated viral vector (AAV) carrying genes
for ChR2 and mCherry (Addgene 20938) were made in either the sensorimotor
cortex or thalamus (encompassing the intralaminar nuclei and parts of the
ventral thalamus) of isoflurane-anesthetized 6-week-old D2BAC-EGFP mice.
The titer was 2 3 109 genomic copies per microliter. Mice were allowed to
recover for at least 2 weeks postinjection. Post hoc visualization of injection
sites was performed in acute slices after recordings.
Gene Expression Profiling
qPCR was used to determine the abundance of transcripts of interest with
procedures similar to that described elsewhere (Chan et al., 2012). To increaseNeuron 83, 178–188, July 2, 2014 ª2014 Elsevier Inc. 185
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Cyc1, Gapdh, H2afz, Hmbs, and Uchl1) were included in order to identify
appropriate reference genes with stable expression across genotypes and
mouse strains. Weighted PCR cycle thresholds based on the stability of
each housekeeping gene were calculated. Experiments for each gene of
interest were run in triplicates. Desalted primers were custom synthesized
(Invitrogen) and intron spanning whenever possible. The mRNA levels in
each subgroup of samples were characterized by their median values. Results
were presented as fold difference relative to the median of their respective
WT controls.
Western Blot Analysis
Coronal brain slices (350 mM) were prepared from isoflurane-anesthetized
mice as described earlier. After recovery in normal ACSF for 30–60 min
(35C), slices were incubated in normal ACSF or ACSF containing 17 mM
KCl (in millimolar: 110 NaCl, 17 KCl, 26 NaHCO3, 1 NaH2PO4, 2 CaCl2, 1
MgCl2, 12.5 glucose; osmolality, 300–305 mOsm
1) for 10 min. Assuming
intracellular K+ concentrations of 120 mM, 17 mM external KCl depolarizes
neurons to the new K+ equilibrium potential of 50.2 mV, evoking both pre-
and postsynaptic activity. After incubation, dorsal striata and overlying cortex
were dissected from each slice, homogenized in tissue extraction reagent I
(Invitrogen) premixed with Halt protease and phosphatase inhibitor cocktail
(Thermo), sonicated, and centrifuged. Supernatants were electrophoresed
on a 4%–12% SDS-polyacrylamide gel, transferred on to a polyvinylidene
difluoride membrane (Invitrogen), blocked with 5% BSA in Tris-buffered saline
with Tween-20, incubated overnight at 4C with primary antibodies, and then
washed and incubated with appropriate anti-rabbit or anti-mouse peroxidase-
conjugated secondary antibodies. Antibodies were BDNF (1:200, Sigma),
phospho-Akt (Ser473, 1:1,000, Cell Signaling), Phospho-TrkB (Y515, 1:500,
Abcam), Akt (1:1,000, Millipore), a-Tubulin (1: 500, Sigma), b-Actin (1:1,000,
Cell Signaling), p75NTR (1:1,000, Millipore), and Gapdh (1:2,000, Abcam).
Immunoreactivity was detected with an enhanced chemiluminescent reagent
(Advansta) and visualized by a ChemiDoc XRS imager (Bio-Rad). The inte-
grated optical density of the target band was quantified in ImageJ (National
Institutes of Health) after background subtraction. The levels of the protein
of interest were expressed as a ratio to the relevant loading controls. Dorsal
striata of both hemispheres of each animal were combined to equal one
sample.
shRNA Knockdown
To silence PTEN expression, we created an AAV serotype 2 vector encoding
for rat PTEN shRNA (siPTEN). The sense, hinge, and siPTEN sequence used
to make the PTEN shRNA was 50-GATCCCCGAGTTCTTCCACAAACAGAA
CTTCCTGTCATTCTGTTTGTGGAAGAACTCTTTTTTGGAAT-30. The integrity
of construct was verified by sequencing. Vector stocks were prepared by
packaging the plasmids into AAV serotype 2 particles using a helper-free
plasmid transfection system (Morgenstern et al., 2011). To silence p75NTR
expression, shRNA oligomers targeting the mouse p75NTR (NM_033217.3)
were created using shRNA design tools. The uniqueness of selected target
sequences was confirmed by a National Center for Biotechnology Information
(NCBI) blast search. Oligos were synthesized from Integrated DNA Tech-
nologies. Three constructs (two shRNA and one control) were created—
p75–p233 shRNA (CAAGGAGACATGTTCCACA), p75–p890 shRNA
(CGCTGACAA CCTCATTCCT), and (AGGATCAAATTGATAGTAAACC), ex-
pressing tdTomato—and were packaged into AAV9 (Virovek). Knockdown of
p75NTR expression was confirmed at the mRNA level by qPCR in PC12 cells.
AAVs were stereotaxically injected into the dorsal striatum as described
earlier. For p75NTR injections, both 233 and 890 constructs were coinjected.
Mice were allowed to recover for at least 2 months before slice experiments
were performed. Infected SPNs were identified by expression of a red fluores-
cent reporter.
NMDA/AMPA Receptor Ratio Measurements
SPNs were voltage clamped with a cesium-based internal recording solution
(described earlier in Sr2+ experiments). Electrically evoked EPSCs were
induced as described elsewhere (Ding et al., 2008). AMPA-receptor-mediated
responses were measured as the peak inward current recorded at a holding186 Neuron 83, 178–188, July 2, 2014 ª2014 Elsevier Inc.potential of 70 mV. NMDAR-mediated responses were measured as the
amplitude of the outward current 50 ms following the stimulus artifact, at a
holding potential of +40 mV. Measurement of EPSC areas in the presence of
the glutamate uptake blocker TBOA was performed as described by others
(Milnerwood et al., 2010). uEPSCs were evoked as described in the Results
and Experimental Procedures. AMPA and NMDAR components of uEPSCs
were measured as described earlier, from holding potentials of 80 mV
and +40 mV, respectively.
Dendrite Morphology and Spine Density Analysis
Dendrite morphology was calculated from low-magnification z series of Alexa
Fluor 568-filled SPNs described earlier. Acquired image stacks were decon-
volved using a 60- to 65-iteration adaptive blind deconvolution algorithm with
AutoQuant X software (MediaCybernetics). The deconvolved image stack was
then imported into the Imaris data visualization package (Bitplane Scientific
Software). Dendritemorphology was analyzed using the filament tracer module
and the incorporated Sholl analysis. For spine density measurements, high-
magnification images of Alexa Fluor 568 dendrites (approximately 90–120 mm
from soma) were obtained as described earlier (pixel size = 0.072 mm2).
Maximum intensity projections (MIPs) were created from 0.5 mm z-steps, and
spines were manually counted along a dendritic region of known distance.
Immunohistochemistry
WTmice were perfused with 4% paraformaldehyde, and 50 mm coronal slices
were made through the dorsolateral striatum. Immunohistochemistry was
performed on free-floating brain slices using a rabbit polyclonal antiserum
made against the intracellular domain of the mouse p75 receptor (1:200
dilution; Millipore) (Huber and Chao, 1995). Detection was achieved using an
Alexa Fluor 488-conjugated anti-rabbit secondary antibody. Slices were
mounted on slides using Vectashield mounting medium and visualized on a
Fluoview FV10i confocal microscope (Olympus).
RNA-Seq
FACS BACHD iSPNs and dSPNs were pooled from four animals (150,000 cells
per animal) to create iSPN and dSPN pools for sequencing. Sequencing was
performed using Expression Analysis on an Illumina HiSeq 2000. Paired-end
sequencing was performed, four-plexed across lanes, for a total of38 million
50-mer paired reads per sample. Alignment and quality control (QC) were con-
ducted in Omicsoft using the Omicsoft sequence aligner algorithm (Hu et al.,
2012); fractions per kilobase of exon per million fragments mapped were
then calculated following standard formulas. QC assessment found all sam-
ples of high quality both at the RNA quality and alignment mapping levels.
For each comparison (BACHD versus WT), significance was assessed using
DESeq (Anders and Huber, 2010) using the single replicate protocol of DESeq.
The resulting RNA-seq data, p values, and fold changes were submitted to
Ingenuity’s upstream regulator analysis, and the confidence of identified
matches was determined with a Fisher’s exact test and connected using
Ingenuity’s knowledge base.
Statistical Analysis
Differences in volume, uEPSC amplitudes, and mRNA expression were exam-
ined using the Mann-Whitney U nonparametric test of significance, unless
otherwise stated. Normality was not assumed for comparisons. Data points
greater than 1.5 SD from the mean were considered outliers and removed.
The percentage of spines that potentiated versus those that did not potentiate
in different experimental groupswas examined using the Fisher’s exact test (or
chi-square test if n > 100), with potentiation defined as 150% of baseline (Fig-
ure 1D). Variance is graphically presented as error bars or box-whisker plots.
Control and experimental groupswere interleavedwhere possible. Differences
were considered statistically significant if p < 0.05.
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